Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-cash Items (2016 - 2025)

Rocket Pharmaceuticals' Non-cash Items history spans 10 years, with the latest figure at $706000.0 for Q4 2025.

  • For Q4 2025, Non-cash Items fell 98.88% year-over-year to $706000.0; the TTM value through Dec 2025 reached $706000.0, down 98.88%, while the annual FY2025 figure was $706000.0, 98.88% down from the prior year.
  • Non-cash Items for Q4 2025 was $706000.0 at Rocket Pharmaceuticals, down from $9.9 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $349.4 million in Q1 2021 and bottomed at $706000.0 in Q4 2025.
  • The 5-year median for Non-cash Items is $111.7 million (2022), against an average of $127.5 million.
  • The largest annual shift saw Non-cash Items skyrocketed 333.28% in 2021 before it tumbled 98.88% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $128.8 million in 2021, then dropped by 7.8% to $118.8 million in 2022, then soared by 111.0% to $250.6 million in 2023, then crashed by 74.74% to $63.3 million in 2024, then crashed by 98.88% to $706000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Non-cash Items are $706000.0 (Q4 2025), $9.9 million (Q3 2025), and $6.5 million (Q2 2025).